Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$98.95 USD

98.95
124,719

+2.28 (2.36%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $98.95 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates

by Zacks Equity Research

At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review

by Zacks Equity Research

Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.

Here's Why Investors Should Hold Universal Health (UHS) Now

by Zacks Equity Research

Universal Health (UHS) benefits from growing patient volumes, sound segmental performance and a solid capital position.

Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

by Zacks Equity Research

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies

by Zacks Equity Research

Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.

Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Ligand (LGND) points to a 44.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

Novo Nordisk (NVO) Announces Positive Obesity Program Data

by Zacks Equity Research

Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

by Zacks Equity Research

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.

Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress

by Zacks Equity Research

Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

by Zacks Equity Research

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study

by Zacks Equity Research

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far

by Zacks Equity Research

Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.

Nilanjan Choudhury headshot

Load Up on These 5 Exceptional Relative Price Strength Stocks

by Nilanjan Choudhury

IDCC, TMHC, NXT, GRBK and LGND are five stocks with explosive relative price strength.

ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why

by Zacks Equity Research

ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.

FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing

by Zacks Equity Research

FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.

Intercept (ICPT) Gains 26.2% YTD: What's in Store?

by Zacks Equity Research

Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).

Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View

by Zacks Equity Research

Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.

Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.

bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

by Zacks Equity Research

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

by Zacks Equity Research

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.